EP300 and acute lymphoblastic leukemia: This case highlights the clinical and molecular complexity of DS-ALL, particularly in the presence of multiple concurrent high-risk alterations (including JAK2, NRAS, and EP300 mutations, the P2RY8-CRLF2 fusion, and iAMP21).